Group 1 - Shanghai is actively expanding high-level opening-up and placing greater emphasis on technological innovation as part of its "14th Five-Year Plan" [2] - The biopharmaceutical industry is one of the three key leading industries in Shanghai, with Boehringer Ingelheim being a global leader in biopharmaceuticals [2] - Shanghai aims to create a long-term, stable, transparent, and predictable development environment to provide new opportunities for global enterprises [2] Group 2 - Boehringer Ingelheim is committed to increasing its innovation investment in Shanghai and collaborating with partners to deepen innovation and research and development [3] - Carl Zeiss AG is focused on leveraging its brand, professional, and innovation advantages to enhance its regional headquarters' functions in Shanghai [3] - Both companies are encouraged to participate in building a more competitive industrial ecosystem and to achieve breakthrough innovations in global markets [3]
为全球企业在沪深耕发展提供新机遇 陈吉宁分别会见勃林格殷格翰股东委员会主席冯保和、蔡司集团总裁兼首席执行官裴安德
Jie Fang Ri Bao·2026-02-09 01:28